Last updated August 29, 2026
Key finding
Physical function scores of SF-36 were significantly improved in Group A.
This study evaluated the impact of sodium-glucose co-transporter-2 inhibitors on quality of life in patients with Type 2 diabetes mellitus, finding significant improvements in various health metrics.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the impact of sodium-glucose co-transporter-2 inhibitors on quality of life in patients with Type 2 diabetes mellitus, finding significant improvements in various health metrics.
These findings are significant as they suggest that SGLT2 inhibitors not only help manage blood sugar levels but also enhance overall quality of life for patients with Type 2 diabetes. This could lead to better adherence to treatment and improved long-term health outcomes.
Limited generalizability due to specific population characteristics. Potential unmeasured confounders affecting outcomes. Short duration of follow-up may not capture long-term effects.
Published in
Publication details and source links for this paper.
Serdar &, Özlem H, Özge PK, et al. The impact of sodium-glucose co-transporter-2 inhibitors on quality of life in patients with Type 2 diabetes mellitus. Turkish Journal of Medical Sciences. 2021;51(2):735-742. doi:10.3906/sag-2008-37
Physical function scores improved by 2.5 points (p=0.001).
Emotional role limitation scores improved by 2 points (p=0.04).
HbA1c levels decreased significantly more in the intervention group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to SGLT2 inhibitors and BMI, Beck Anxiety Inventory (BAI), Body weight, and 9 more.
This study contributes evidence to
Primary intervention
SGLT2 inhibitors
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
12
Evidence pairs
743
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
SGLT2 inhibitors → Beck Anxiety Inventory (BAI)
SGLT2 inhibitors → Beck Anxiety Inventory (BAI)
SGLT2 inhibitors → Change in Bodily Pain Domain of Health-Related Quality of Life
SGLT2 inhibitors → Change in Bodily Pain Domain of Health-Related Quality of Life
SGLT2 inhibitors → Change in perception of health
SGLT2 inhibitors → Change in perception of health
SGLT2 inhibitors → Role limitation due to emotional problems score
SGLT2 inhibitors → Role limitation due to emotional problems score
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Body Mass Index.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Body Mass Index
Measures Body Mass Index as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
3 results
2 results
3 results
3 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 22 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of SGLT2 Inhibitors for Quality of Life Outcomes.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Sleep quality
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
